HSCS Heart Test Laboratories Inc.: Multiplikator Forward P/S
Heart Test Laboratories is developing a digital AI-electrocardiography ecosystem where cloud services and MyoVista devices create high switching costs for clinics. The expected P/S valuation visualizes this trend, with the 774.80 mark indicating the current multiple level. Screening automation via neural networks minimizes the role of physicians, while business success depends on the demand for early diagnosis amid stable capital.
Rincian metrik komprehensif lan analitis Heart Test Labs (HSCS)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Heart Test Laboratories|HSCS - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Heart Test Laboratories|HSCS - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Heart Test Labs|HSCS - Utang jangka dawa|Utang jangka cendhak perusahaan HeartSciences|Indikator likuiditas cepet heartsciences.com
- data bathi bisnis lan rasio investasi:
HSCS - Bathi sawise mbayar pajeg|Bathi mangsa ngarep Heart Test Laboratories|HSCS - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Heart Test Laboratories Inc.|HSCS - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA Heart Test Labs|HSCS - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) HeartSciences|HSCS - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan heartsciences.com|HSCS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Heart Test Laboratories
- statistik dodolan lan pendapatan perusahaan:
Analisis umum perusahaan:HeartSciences HSCS
The forward P/S reflects the market value of Heart Test Laboratories (HSCS) relative to its projected sales, allowing for an assessment of the degree of investor optimism currently priced in. By analyzing the expected revenue multiple, one can compare the commercialization pace of AI-driven cardiac pathology diagnostics with the company's capitalization, which helps manage equipment implementation risks provided there is sufficient liquidity.
Analisis pesaing
Multiplikator Forward P/S A (Agilent)|Quest Diagnostics Inc. (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Illumina Corp - Multiplikator Forward P/S|EXAS - Multiplikator Forward P/S|Revvity, Inc. (RVTY) - Rasio rega marang prakiraan pendapatan|bio-rad.com - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan NNNN|SHC (Sotera Health Corp) - Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan QDEL (QuidelOrtho Corp)|OPK (OPKO Health Corp.) - Rega forward marang dodolan|CareDx, Inc - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake MRVI (maravai.com)|Fulgent Genetics - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Standard BioTools Inc|Cytek Bio (CTKB) - Rasio rega marang prakiraan pendapatan|OSUR - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan XGN|MDXH (mdxhealth.com) - Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan LUCD (Lucid Diagnostics)|PRE (prenetics.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Insight Molecular Diagnostics Inc IMDX|Trinity Biotech PLC - Rasio rega marang prakiraan pendapatan|ProPhase Labs, Inc. - Multiplikator Forward P/S|AIMD - Multiplikator Forward P/S|CODX: Multiplikator Forward P/S|BMRA (Biomerica Inc.) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Cardio Diagnostics Holdings Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Onconetix Corporation ONCO|Rasio rega marang prakiraan pendapatan Virax Biolabs Group (VRAX)|BJDX (bluejaydx.com) - Rega forward marang dodolan|Multiplikator Forward P/S AWH (Aspira Women's Health Inc.)|Multiplikator Forward P/S Accelerate Diagnostics Inc. AXDX|CNTG: Multiplikator forward rega marang pendapatan|Enzo Biochem, Inc. - Rasio rega marang pendapatan sing dikarepake|fresh2.co (FRES) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Genetic Technologies Limited (GENE)|Rasio rega marang prakiraan pendapatan 23andMe|PMD: Rega forward marang dodolan
